Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.69 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 2/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4039907 | 0.93 | CTSK (0.59) | CTSKCTSSACE | |
| SCHEMBL4042794 | 0.92 | CTSK (0.57) | CTSKCTSSALDH1A1ACEPREP | |
| SCHEMBL4044197 | 0.92 | CTSK (0.63) | CTSKCTSSLMNAACEPREP | |
| SCHEMBL4049108 | 0.92 | CTSK (0.57) | CTSKCTSSALDH1A1LMNAMAPT | |
| SCHEMBL4037811 | 0.92 | CTSK (0.57) | CTSKCTSSALDH1A1LMNAMAPT | |
| SCHEMBL4047037 | 0.92 | CTSK (0.56) | CTSKCTSSALDH1A1LMNAACE | |
| SCHEMBL5941894 | 0.91 | CTSK (0.80) | CTSKCTSSALDH1A1MEN1KMT2A | |
| SCHEMBL5941898 | 0.91 | CTSK (0.80) | CTSKCTSSALDH1A1MEN1KMT2A | |
| SCHEMBL4042814 | 0.91 | CTSK (0.80) | CTSKCTSSALDH1A1MEN1KMT2A | |
| SCHEMBL4215397 | 0.91 | CTSK (0.80) | CTSKCTSSALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| EP-2021344-A1 | BICYCLIC ENAMINO(THIO)CARBONYL COMPOUNDS | Bayer CropScience AG (DE) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007115647-A1 | BICYCLIC ENAMINO(THIO)CARBONYL COMPOUNDS | BAYER CROPSCIENCE AG (DE) | 2007-10-18 | — | — | WO | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | CTSK 2/4885CTSS 3/4885ALDH1A1 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.